A new method to treat heart muscle thickening in patients who can't have surgery
A Controlled Septal Ablation for Inoperable Hypertrophic Cardiomyopathy
This study is exploring a new, safer way to treat hypertrophic cardiomyopathy (HCM) by using a gentle technique to help reduce the thickened heart muscle, so patients can feel better without needing major surgery.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Arlington NIH-funded |
| Lab location | 1 site (Arlington, United States) |
| Project ID | NIH-10514872 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treat hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens, causing obstruction in blood flow. The current treatment, alcohol septal ablation, can lead to serious complications due to the uncontrolled nature of alcohol diffusion. This project aims to develop a safer and more effective ablation system that minimizes risks while effectively targeting the thickened heart muscle. Patients will be treated using a minimally invasive technique that could provide relief from symptoms without the need for open-heart surgery.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with hypertrophic cardiomyopathy who have not responded adequately to medication and are considered poor candidates for surgical intervention.
Not a fit: Patients with mild hypertrophic cardiomyopathy or those who are suitable for traditional surgical options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer treatment option for patients with hypertrophic cardiomyopathy who are not candidates for traditional surgery.
How similar studies have performed: While alcohol septal ablation has been widely used, this research aims to innovate beyond existing methods, making it a novel approach in the field.
Where this research is happening
Arlington, United States
- University of Texas Arlington — Arlington, United States (Active)
Researchers
- Principal investigator: Liao, Jun — University of Texas Arlington
- Study coordinator: Liao, Jun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.